Targeted immunotherapy designed to treat MUC1-expressing solid tumour

Current Topics in Microbiology and Immunology

Volumn 405, Issue , 2017, Pages 79-97

  Acres, Bruce ^b   Lacoste, Gisele ^a   Limacher, Jean Marc ^a  

^a TRANSGENE S A   (France)

^b Bruce Acres Consulting   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AS 1402; FALIMAREV; HYBRID PROTEIN; KEYHOLE LIMPET HEMOCYANIN; MANNAN FUSION PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AR20.5; MONOCLONAL ANTIBODY C595 CU 67; MONOCLONAL ANTIBODY C595 IN 111; MONOCLONAL ANTIBODY NCRC48 IN 111; MUCIN 1; RNA VACCINE; TECEMOTIDE; TG 4010; UNCLASSIFIED DRUG; CANCER VACCINE; MUC1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; KIDNEY CANCER; LUNG CANCER; METASTATIC BREAST CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID MALIGNANT NEOPLASM; T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASM;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MUCIN-1; NEOPLASMS;

EID: 85024105745     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_429     Document Type: Chapter

References (96)

1. Editorial (2013) Do no harm. Nat Biotechnol 31(5):365. doi: 10.310.1038/nbt.2587
2. Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, Bizouarne N, Kieny MP, McKenzie IF (2000) MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother 48(10):588-594
3. Acres B, Limacher JM (2005) MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4(4): 493-502
4. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159(11):5211-5218
5. Apostolopoulos V, Osinski C, McKenzie IF (1998) MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat Med 4(3):315-320
6. Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S (2006) Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res 8(3):R27
7. Apostolopoulos V, Pietersz GA, Xing PX, Lees CJ, Michael M, Bishop J, McKenzie IF (1995) The immunogenicity of MUC1 peptides and fusion protein. Cancer Lett 90(1):21-26
8. Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W (2006) Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr Cancer Drug Targets 6(4):271-294
9. Baldwin RW (1955) Immunity to methylcholanthrene-induced tumours in inbred rats following atrophy and regression of the implanted tumours. Br J Cancer 9(4):652-657
10. Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific, major histocompatibility complexunrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 86(18):7159-7163
11. Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, Eisenbach L, Zavazava N, Admon A (2002) Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 32(1):213-222
12. Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, Weiss M, Smorodinsky N, Wreschner DH (1997) Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer 71 (5):741-749
13. Billingham RE, Brent L, Medawar PB (1953) Actively acquired tolerance of foreign cells. Nature 172(4379):603-606
14. de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW (2004) Phase l trial of a murine antibody to Muc1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 15(12):1825-1833
15. Brenner TL, Adams VR (1999) First MAb approved for treatment of metastatic breast cancer. J Am Pharm Assoc (Wash) 39(2):236-238
16. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93(12): 4309-4317
17. Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D (1987) Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47(20):5476-5482
18. Burchell J, Taylor-Papadimitriou J (1993) Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2(4):155-162
19. Burchell J, Wang D, Taylor-Papadimitriou J (1984) Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int J Cancer 34(6):763-768
20. Burnet FM (1960) Theories of immunity. Perspect Biol Med 3:447-458
21. Butts C, Maksymiuk A, Goss G, Soulières D, Marshall E, Cormier Y, Ellis PM, Price A, Sawhney R, Beier F, Falk M, Murray N (2011) Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 137(9):1337-1342
22. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulières D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M (2005) Randomized phase llb trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23(27):6674-6681
23. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquee L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schroder A, Shepherd FA, Team S.t (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15(1): 59-68
24. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15 (17):5323-5337
25. Coca AF, Lebredo MG (1912) A report of the results of the vaccination therapy as applied in 79 cases of Human Cancer. Z Immunitatsforschung und Exp 13:543-585
26. Coca AF (1909) The specific treatment of carcinoma. Philippine J Sci 4(6):391-402
27. Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105(5):487-511
28. Coley WB (1906) Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus. Am J Med Sci 131(3):377-430
29. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG (2011) Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 71(4):1253-1262
30. Dalziel M, Whitehouse C, McFarlane I, Brockhausen I, Gschmeissner S, Schwientek T, Clausen H, Burchell JM, Taylor-Papadimitriou J (2001) The relative activities of the C2GnT1 and ST3Gal-I glycosyltransferases determine O-glycan structure and expression of a tumorassociated epitope on MUC1. J Biol Chem 276(14):11007-11015
31. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tumantigen P91A and identification of the tum-mutation. Proc Natl Acad Sci U S A 85(7): 2274-2278
32. Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS, Samad KA, Phillips CA, Robinson W, Dobrzanski DJ, Wright SE (2009) Autologous Muc1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol 133(3):333-352
33. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A (2009) MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 27 (4):379-386
34. Eichmuller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D (2001) Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A 98 (2):629-634
35. Foley EJ (1953) Attempts to induce immunity against mammary adenocarcinoma in inbred mice. Cancer Res 13(8):578-580
36. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-risk breast cancer patients with mucin-1 (Muc1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693-1701
37. Gong J, Chen D, Kashiwaba M, Li Y, Chen L, Takeuchi H, Qu H, Rowse GJ, Gendler SJ, Kufe D (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci U S A 95(11):6279-6283
38. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144
39. Hanisch FG, Schwientek T, Von Bergwelt-Baildon MS, Schultze JL, Finn O (2003) O-Linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells. Eur J Immunol 33(12): 3242-3254
40. Harris JR, Price MR, Baldwin RW (1973) The purification of membrane-associated tumour antigens by preparative polyacrylamide gel electrophoresis. Biochim Biophys Acta 311 (4):600-614
41. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 190(1):145-150
42. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (7528):563-567
43. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R (2001) Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91(3):385-392
44. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ (2000) The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165(7):3730-3741
45. Hughes OD, Perkins AC, Frier M, Wastie ML, Denton G, Price MR, Denley H, Bishop MC (2001) Imaging for staging bladder cancer: a clinical study of intravenous 111 Indium-labelled anti-Muc1 mucin monoclonal antibody c595. BJU Int 87(1):39-46
46. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M (2011) Randomized phase ll trial of letrozole plus anti-muc1 antibody as1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 17(21): 6822-6830
47. Jonckheere N, Van Seuningen I (2010) The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie 92(1):1-11
48. Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF (2001) Mannan mucin-1 peptide immunization: Influence of cyclophosphamide and the route of injection. J Immunother 24(2):172-183
49. Keydar I, Chou CS, Hareuveni M, Tsarfaty I, Sahar E, Selzer G, Chaitchik S, Hizi A (1989) Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc Natl Acad Sci U S A 86(4):1362-1366
50. Kim YD, Robinson DY, Tomita JT (1988) Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma. Cancer Res 48(16):4543-4548
51. Kimura T, Finn OJ (2013) MUC1 immunotherapy is here to stay. Expert Opin Biol Ther 13(1): 35-49
52. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495-497
53. Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K, Takashima M, Ueno T, Hinoda Y, Oka M (2008) Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 28(1B):379-387
54. Kunkler RB, Bishop MC, Green DJ, Pimm MV, Price MR, Frier M (1995) Targeting of bladder cancer with monoclonal antibody NCRC48-a possible approach for intravesical therapy. Br J Urol 76(1):81-86
55. Lan MS, Khorrami A, Kaufman B, Metzgar RS (1987) Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The DU-PAN-2 antigen. J Biol Chem 262 (26):12863-12870
56. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK (2008) A phase l/ll study of a Muc1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6(B):955-964
57. Limacher JM, Acres B (2014) MUC1 as a therapeutic target in cancer. In: ‘Mucins and Cancer’ Future Medicine, pp 125-137
58. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL (2006) Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 12(3 Pt 1):869-877
59. Maloney DG (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366 (21):2008-2016
60. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK (2013) A randomized phase ll study of immunization with dendritic cells modified with poxvectors encoding cea and muc1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 7:7
61. Nath S, Mukherjee P (2014) MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20(6):332-342
62. Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG (2009) Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 47(1):131-140
63. Noto H, Takahashi T, Makiguchi Y, Hayashi T, Hinoda Y, Imai K (1997) Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 9(5):791-798
64. O’Mahony D, Kummar S, Gutierrez ME (2005) Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol 23(35):9022-9028
65. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E (2011) A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60(2):261-271
66. Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52(7): 1954-1960
67. Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N (2009) Phase l dose escalation pharmacokinetic assessment of intravenous humanized anti-Muc1 antibody as1402 in patients with advanced breast cancer. Breast Cancer Res 11(5):R73
68. Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, Mandel U, Dell A, Pinder S, Taylor-Papadimitriou J, Burchell J (2010) Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology 20(10):1241-1250
69. Powell E, Chow LQ (2008) BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer. Expert Rev Respir Med 2(1):37-45
70. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18(6):769-778
71. Quoix E, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Felip E, Debieuvre D, Madroszyk A, Lacoste G, Tavernaro A, Bastien B, Palanche T, Limacher J-M (2014) TIME, a phase 2b/3 study evaluating TG4010 in combination with first line therapy advanced non small cell lung cancer (NSCLC). Phase 2b results. In: 39th ESMO congress, Madrid 2014—European Society for Medical Oncology esmocongress.org. Abstract 5152
72. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12(12):1125-1133
73. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, Limacher JM, Bizouarne N, Acres B, Halluard C, Velu T (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV nonsmall cell lung cancer. J Thorac Oncol 3(7):735-744
74. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, Horger MS, Maksimovic O, Stenzl A, Hoerr I, Rammensee HG, Holderried TA, Kanz L, Pascolo S, Brossart P (2011) Intradermal vaccinations with RNA coding for taa generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 19(5):990-999
75. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R (2012) Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Trans Med 10:236
76. Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A (2014) Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 3: e29244
77. Roulois D, Gregoire M, Fonteneau JF (2013) MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge. Biomed Res Int 2013:871936
78. Roulois D, Vignard V, Gueugnon F, Labarriere N, Gregoire M, Fonteneau JF (2011) Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8 + T-cells. Eur Respir J 38(5):1117-1126
79. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58(2):315-321
80. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B, Pouillart P, Taylor-Papadimitriou J, Miles D (2003) Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003(3):194-201
81. Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW (1985) Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol 3(10):1355-1363
82. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H (2006) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancerspecific anti-MUC1 antibody responses and override tolerance. Glycobiology 16(2):96-107
83. Stacker SA, Tjandra JJ, Xing PX, Walker ID, Thompson CH, McKenzie IF (1989) Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2. Br J Cancer 59(4):544-553
84. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, Yachi A (1994) Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153(5):2102-2109
85. Tang CK, Apostolopoulos V (2008) Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 7(7):951-962
86. Tarp MA, Sorensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H (2007) Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17(2):197-209
87. Tempero RM, Rowse GJ, Gendler SJ, Hollingsworth MA (1999) Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer 80(4):595-599
88. Therion Biologics press release (2006) http://www.prnewswire.com/news-releases/therion-reportsresults-of-phase-3-panvac-vf-trial-and-announces-plansfor-company-sale-56997582.html
89. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571
90. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr, Hanisch FG, Finn OJ (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196(11):1435-1446
91. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18(3):574-583
92. Wajchman HJ, Pierce CW, Varma VA, Issa MM, Petros J, Dombrowski KE (2004) Ex vivo expansion of CD8+ CD56+ and CD8+ CD56− natural killer T cells specific for MUC1 mucin. Cancer Res 64(3):1171-1180
93. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H (2010) Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 70(4):1306-1313
94. Weber JS (2014) Immuno-oncology comes of age-introduction. Semin Oncol 41(5): S1-2. doi: 10.1053/j.seminoncol.2014.1009.1002. (Epub 2014 Sep 1056)
95. Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Philip R, Zorsky P, Klug P, Dai L, Hussain M, Thomas AA, Sundaramurthy C (2009) Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients-a phase l/ll study. Immunol Invest 38(8):820-838
96. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T (2011) INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 11:430